It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Mammalian hearing requires the development of the organ of Corti, a sensory epithelium comprising unique cell types. The limited number of each of these cell types, combined with their close proximity, has prevented characterization of individual cell types and/or their developmental progression. To examine cochlear development more closely, we transcriptionally profile approximately 30,000 isolated mouse cochlear cells collected at four developmental time points. Here we report on the analysis of those cells including the identification of both known and unknown cell types. Trajectory analysis for OHCs indicates four phases of gene expression while fate mapping of progenitor cells suggests that OHCs and their surrounding supporting cells arise from a distinct (lateral) progenitor pool. Tgfβr1 is identified as being expressed in lateral progenitor cells and a Tgfβr1 antagonist inhibits OHC development. These results provide insights regarding cochlear development and demonstrate the potential value and application of this data set.
How the development of the cochlear epithelium is regulated is unclear. Here, the authors use single cell RNAseq analysis to provide insight into the transcriptional changes arising during development of the murine cochlear inner and outer hair cells.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 National Institutes of Health, Laboratory of Cochlear Development, National Institute on Deafness and Other Communication Disorders, Bethesda, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165)
2 King’s College London, Centre for Craniofacial and Regenerative Biology, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764)
3 Decibel Therapeutics, Boston, USA (GRID:grid.94365.3d)
4 University of Maryland School of Medicine, Institute for Genome Sciences, Baltimore, USA (GRID:grid.411024.2) (ISNI:0000 0001 2175 4264)
5 Decibel Therapeutics, Boston, USA (GRID:grid.411024.2)
6 University of Maryland School of Medicine, Institute for Genome Sciences, Baltimore, USA (GRID:grid.411024.2) (ISNI:0000 0001 2175 4264); University of Maryland School of Medicine, Department of Otorhinolaryngology Head and Neck Surgery, Anatomy and Neurobiology, and Institute for Genome Sciences, Baltimore, USA (GRID:grid.411024.2) (ISNI:0000 0001 2175 4264)